HLA-A2 restricted, melanocyte-specific CD8+ T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1

Journal of Investigative Dermatology

Volumn 116, Issue 6, 2001, Pages 891-897

  Lang, Karl Sebastian ^b   Caroli, Constanze Charlotte ^a   Muhm, Alexandra ^b   Wernet, Dorothee ^a   Moris, Arnaud ^b   Schittek, Birgit ^a   Knauss Scherwitz, Evelyn ^a   Stevanovic, Stefan ^b   Rammensee, Hans Georg ^b   Garbe, Claus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b NONE

Author keywords

ELISPOT; gp100; Intracellular IFN staining; Tyrosinase

Indexed keywords

HLA A2 ANTIGEN;

ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; MELANOCYTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VITILIGO;

EID: 0034990633     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.2001.01363.x     Document Type: Article

References (43)

1. Tyrosinase as an autoantigen in patients with vitiligo
2. Accumuladon of identical T cells in melanoma and vitiligo-like leukoderma
3. The minimum peptide epitope from the influenza virus matrix protein. Extra and intracellular loading of HLA-A2
4. Mass spectrometric identification of a naturally processed melanoma pepfide recognized by CD8+ cytotoxic T lymphocytes
5. Vitiligo associated with metastatic malignant melanoma
6. Vitiligo, psoralen, and melanogenesis: Some observations and understanding
7. A new gene coding for a differentiation antigen reconized by autologous cytolytic T lymphocytes on HLA-A2 melanomas
8. Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines
9. Melanoma and vitiligo are associated with antibody responses to similar antigens on pigment cells
10. Prolonged survival in metastatic malignant melanoma associated with vitiligo
11. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF) -producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation
12. Autoantibodies to tyrosinase: The bridge between melanoma and vitiligo
13. Study of HLA class I/IL and T lymphocyte subsets in Kuwaiti vitiligo patients
14. Cytomegalovirus DNA identified in skin biopsy specimens of patients with vitiligo
15. Detection of antibodies to human melanoma cell in vitiligo by western blot analysis
16. Detection of antibodies to human melanoma cells in vitiligo and alopecia areata by Western blot analysis
17. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry
18. Dendritic cells containing apoptotic melanoma cells prime human CD8+ T cells for efficient tumor cell lysis
19. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
20. Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression
21. Vitiligo-like depigmentation and morpheas after specific intralymphatic immunotherapy for malignant melanoma
22. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance
23. Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients
24. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2
25. Peripheral T-cell activation in non-segmental vitiligo
26. Increased sensitivity to peroxidative agents as a possible pathogenic factor of melanocyte damage in vitiligo
27. T cell subpopulations in vitiligo: A chronobiologic study
28. Detection of antibodies to melanocytes in vitiligo by specific immunoprecipitation
29. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
30. Vitiligo in patients with metastatic melanoma: A good prognostic sign
31. Evidence for immunologic mechanisms in human vitiligo: Patients' sera induce damage to human melanocytes in vitro by complement-mediated damage and antibody-dependent cellular cytotoxicity
32. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo
33. Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: Requirement for CD4(+) T lymphocytes
34. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA) -A 2 individuals
35. Cytolytic T lymphocyte recognition of the immunodominant HLA-A*0201-restricted Melan-A/MART-1 antigenic peptide in melanoma
36. Vitiligo in patients with melanoma: Normal tissue antigens can be targets for cancer immunotherapy
37. Resistance to natural killer cell lysis conferred by TAP1/2 genes in human antigen-processing mutant cells
38. An HLA-A2-restricted tyrosinase antigen on melanoma cells results from posttranslational modification and suggests a novel pathway for processing of membrane proteins
39. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response
40. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues
41. Recruitment during infectious mononucleosis of CD3+CD4+CD8+ virus-specific cytotoxic T cells which recognise Epstein-Barr virus lytic antigen BHRF1
42. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp 65: Frequency, specificity, and T-cell receptor usage of pp 65-specific CTL
43. Meyer zBKH Boon T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by autologous cytolytic T lymphocytes